Skip to main content

Table 1 Patient characteristics and concomitant medication

From: Effectiveness and safety of ferric carboxymaltose treatment in children and adolescents with inflammatory bowel disease and other gastrointestinal diseases

Total n 72
Gender, n (%)  
     Male 35 (48.6)
     Female 37 (51.4)
Age, years  
     Mean (SD) 11.8 (4.86)
     Min, max 0, 18
     Median 13.5
     Interquartile range 8, 15.5
Previous oral iron use, n (%) 39 (54.2)
Medical history, n (%)  
     Crohn’s disease 29 (40.3)
     Ulcerative colitis 22 (30.5)
     Celiac disease 4 (5.6)
     Gastroesophageal reflux disease 2 (2.8)
     Helicobacter pylori gastritis 2 (2.8)
     Oesophageal varices bleeding 2 (2.8)
     Chronic diarrhoea 1 (1.4)
     Hyper-IgM syndrome 1 (1.4)
     Intestinal vascular malformation 1 (1.4)
     Ulcus ventriculi 1 (1.4)
     Others 7 (9.7)
Concomitant medication, n (%)  
     Any medication 69 (95.8)
     Prednisolone 30 (41.7)
     Azathioprine 29 (40.3)
     Mesalazine 34 (47.2)
     Omeprazole 31 (43.1)
     Ferrous glycine sulphate 15 (20.8)
     Metronidazole 10 (13.9)
     Infliximab 9 (12.5)
     Escherichia coli Nissle 1917 9 (12.5)
     Cyclosporine 5 (6.9)
  1. Most often used concomitant medication taken at any time during the observation period (i.e. 3 months prior and 3 months post administration of FCM). SD: Standard deviation.